Amy S Baranoski1, Elizabeth A Stier. 1. Department of Medicine, Section of Infectious Diseases, Boston University School of Medicine, Boston, MA 02118, USA. amy.baranoski@bmc.org
Abstract
BACKGROUND: HIV-infected women are at increased risk for cervical dysplasia and require timely follow-up after an abnormal Papanicolaou (Pap) test. METHODS: This retrospective cohort study assessed the proportion of HIV-infected women with colposcopic evaluation after an abnormal Pap test. Time to colposcopy within 12 months after an abnormal Pap test was assessed with univariate and multivariate Cox proportional hazard modeling in a diverse cohort of HIV-infected women between October 1, 2003, and September 30, 2007. RESULTS: One hundred seventy-seven subjects had an abnormal Pap test: 22 high-grade intraepithelial lesion (HSIL; 12%), 120 low-grade squamous intraepithelial lesion (LSIL; 68%), and 35 atypical squamous cells of undetermined significance, human papillomavirus positive (20%). One hundred twenty (68%) had follow-up colposcopy by 1 year. Decreased time to follow-up was associated with being married (HR 3.5, 95% CI 1.9-6.2), high school graduate or higher education level (HR 1.7, CI 1.2-2.6), HSIL Pap results (HR 2.8, CI 1.3-6.2), Pap testing performed by HIV nurse practitioner versus gynecology clinic (HR 1.7, 1.1-2.7), and CD4 count ≥500 cells/mm(3) (HR 1.8, CI 1.2-2.8), after adjusting for age, race/ethnicity, and LSIL Pap result. Private insurance was associated with decreased time to colposcopy in unadjusted, but not multivariate analysis. Drug use was not associated with time to follow-up colposcopy. CONCLUSIONS: Almost one third of HIV-infected women did not have a follow-up colposcopy by 12 months after an abnormal Pap test. Since HIV-infected women are at particularly high risk for cervical cancer, these results are unacceptably poor. Identification of the barriers to appropriate follow-up and targeted interventions are necessary to improve timely follow-up for cytologic abnormalities in this high-risk population.
BACKGROUND:HIV-infectedwomen are at increased risk for cervical dysplasia and require timely follow-up after an abnormal Papanicolaou (Pap) test. METHODS: This retrospective cohort study assessed the proportion of HIV-infectedwomen with colposcopic evaluation after an abnormal Pap test. Time to colposcopy within 12 months after an abnormal Pap test was assessed with univariate and multivariate Cox proportional hazard modeling in a diverse cohort of HIV-infectedwomen between October 1, 2003, and September 30, 2007. RESULTS: One hundred seventy-seven subjects had an abnormal Pap test: 22 high-grade intraepithelial lesion (HSIL; 12%), 120 low-grade squamous intraepithelial lesion (LSIL; 68%), and 35 atypical squamous cells of undetermined significance, human papillomavirus positive (20%). One hundred twenty (68%) had follow-up colposcopy by 1 year. Decreased time to follow-up was associated with being married (HR 3.5, 95% CI 1.9-6.2), high school graduate or higher education level (HR 1.7, CI 1.2-2.6), HSIL Pap results (HR 2.8, CI 1.3-6.2), Pap testing performed by HIV nurse practitioner versus gynecology clinic (HR 1.7, 1.1-2.7), and CD4 count ≥500 cells/mm(3) (HR 1.8, CI 1.2-2.8), after adjusting for age, race/ethnicity, and LSIL Pap result. Private insurance was associated with decreased time to colposcopy in unadjusted, but not multivariate analysis. Drug use was not associated with time to follow-up colposcopy. CONCLUSIONS: Almost one third of HIV-infectedwomen did not have a follow-up colposcopy by 12 months after an abnormal Pap test. Since HIV-infectedwomen are at particularly high risk for cervical cancer, these results are unacceptably poor. Identification of the barriers to appropriate follow-up and targeted interventions are necessary to improve timely follow-up for cytologic abnormalities in this high-risk population.
Authors: Vicki B Benard; Herschel W Lawson; Christie R Eheman; Christa Anderson; William Helsel Journal: Obstet Gynecol Date: 2005-06 Impact factor: 7.661
Authors: Linda P Engelstad; Susan Stewart; Regina Otero-Sabogal; May S Leung; Patricia I Davis; Rena J Pasick Journal: Prev Med Date: 2005 Sep-Oct Impact factor: 4.018
Authors: Ann L Coker; Katherine S Eggleston; Tamra E Meyer; Kathryn Luchok; Irene Prabhu Das Journal: Gynecol Oncol Date: 2006-12-08 Impact factor: 5.482
Authors: C Six; I Heard; C Bergeron; G Orth; J D Poveda; P Zagury; P Cesbron; C Crenn-Hébert; R Pradinaud; M Sobesky; C Marty; M L Babut; J E Malkin; A Odier; S Fridmann; J P Aubert; J B Brunet; I de Vincenzi Journal: AIDS Date: 1998-06-18 Impact factor: 4.177
Authors: Alison G Abraham; Gypsyamber D'Souza; Yuezhou Jing; Stephen J Gange; Timothy R Sterling; Michael J Silverberg; Michael S Saag; Sean B Rourke; Anita Rachlis; Sonia Napravnik; Richard D Moore; Marina B Klein; Mari M Kitahata; Gregory D Kirk; Robert S Hogg; Nancy A Hessol; James J Goedert; M John Gill; Kelly A Gebo; Joseph J Eron; Eric A Engels; Robert Dubrow; Heidi M Crane; John T Brooks; Ronald J Bosch; Howard D Strickler Journal: J Acquir Immune Defic Syndr Date: 2013-04-01 Impact factor: 3.731
Authors: Arti Barnes; Andrea C Betts; Eric K Borton; Joanne M Sanders; Sandi L Pruitt; Claudia Werner; Andres Bran; Carolee D Estelle; Bijal A Balasubramanian; Stephen J Inrig; Ethan A Halm; Celette Sugg Skinner; Jasmin A Tiro Journal: AIDS Date: 2018-08-24 Impact factor: 4.177